This trial is active, not recruiting.

Conditions chronic kidney disease, heart rate variability
Sponsor National Taiwan University Hospital
Start date December 2009
End date June 2010
Trial size 300 participants
Trial identifier NCT00824577, 200812010R


Use 24hr Holter ECG, ultrasound and cardiac fibrosis markers in the chronic kidney disease patients

United States No locations recruiting
Other countries No locations recruiting

Study Design

Observational model cohort
Time perspective cross-sectional
heart rate variability, heart function and Kt/V

Primary Outcomes

heart rate variability, heart function, PET, Kt/V
time frame: 12 months

Eligibility Criteria

Male or female participants from 15 years up to 90 years old.

Inclusion Criteria: - peritoneal dialysis more than 3 months Exclusion Criteria: - pregnancy 2. received CT in recent 3 months

Additional Information

Official title Heart Rate Variability in Chronic Kidney Disease Patients
Description 24hr Holter examination is a non-invasive tool in detecting and diagnosing cardiac arrhythmia. Moreover, Heart rate variability has been proven to been an important prognostic factor in many cardiovascular diseases. The traditional linear analysis of heart rate variability proved to predict clinical outcome in myocardial infarction patients. The more delicate non-linear analysis in heart rate variability is one of the hot topics in the world. Despite some biochemical values like WBC counts, platelet counts, BUN, creatinine, lactate, clinical vital parameters like blood pressure, heart rate, and oxygenation have been used to predict clinical outcome in chronic renal disease(CKD) patients, the application is still limited. It is an international interest to find a more safe and simple technique to identify important prognostic factors in CKD patients. Our project aimed to recruit these CKD patients from our hospital and conduct a cross-sectional study. Cardiac ultrasonography and 24hrs Holter will be arranged. Linear and non-linear analysis of heart rate variability will be performed and serum marker that influence prognosis like WBC count, platelet count, lactate, BUN, creatinine, fibrosis marker and adiponectin will be checked. Short term and long term outcome was followed and identify important prognostic factors to improve and detect clinical prognosis.
Trial information was received from ClinicalTrials.gov and was last updated in June 2010.
Information provided to ClinicalTrials.gov by National Taiwan University Hospital.